Takacs Michael1, Frass Michael2, Walder Gernot3, Fibert Philippa4, Rottensteiner Maria5, Glück Walter5, Lechleitner Peter1, Oberbaum Menachem6, Leisser Ilse7, Chandak Kavita8, Panhofer Peter9, Weiermayer Petra10
Complement Ther Clin Pract. 2021 May 11;44:101415. doi: 10.1016/j.ctcp.2021.101415. Online ahead of print.
Background: and purpose. COVID-19 is a novel viral disease causing worldwide pandemia. The aim of this study was to describe the effect of adjunctive individualized homeopathic treatment delivered to hospitalized patients with confirmed symptomatic SARS-CoV-2 infection.
Patient presentation: Thirteen patients with COVID-19 were admitted. Mean age was 73.4 ± 15.0 (SD) years. Twelve (92.3%) were speedily discharged without relevant sequelae after 14.4 ± 8.9 days. A single patient admitted in an advanced stage of septic disease died in hospital. A time-dependent improvement of relevant clinical symptoms was observed in the 12 surviving patients. Six (46.2%) were critically ill and treated in the intensive care unit (ICU). Mean stay at the ICU of the 5 surviving patients was 18.8 ± 6.8 days. In six patients (46.2%) gastrointestinal disorders accompanied COVID-19.
Conclusion: The observations suggest that adjunctive homeopathic treatment may be helpful to treat patients with confirmed COVID-19 even in high – risk patients especially since there is no conventional treatment of COVID-19 available at present.
Keywords: COVID-19; Complementary therapies; Homeopathy; Intensive care unit; SARS-CoV-2.